- Home
- SWIM vs IVA Comparison
SWIM vs IVA Comparison
Compare SWIM & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- IVA
- Stock Information
- Founded
- SWIM 1956
- IVA 2011
- Country
- SWIM United States
- IVA France
- Employees
- SWIM N/A
- IVA N/A
- Industry
- SWIM Plastic Products
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- SWIM Industrials
- IVA Health Care
- Exchange
- SWIM Nasdaq
- IVA Nasdaq
- Market Cap
- SWIM 839.1M
- IVA 769.0M
- IPO Year
- SWIM 2021
- IVA 2020
- Fundamental
- Price
- SWIM $7.27
- IVA $4.55
- Analyst Decision
- SWIM Hold
- IVA Strong Buy
- Analyst Count
- SWIM 3
- IVA 8
- Target Price
- SWIM $7.10
- IVA $17.13
- AVG Volume (30 Days)
- SWIM 751.3K
- IVA 288.0K
- Earning Date
- SWIM 11-04-2025
- IVA 09-29-2025
- Dividend Yield
- SWIM N/A
- IVA N/A
- EPS Growth
- SWIM N/A
- IVA N/A
- EPS
- SWIM N/A
- IVA N/A
- Revenue
- SWIM $533,235,000.00
- IVA $19,929,536.00
- Revenue This Year
- SWIM $9.17
- IVA N/A
- Revenue Next Year
- SWIM $5.38
- IVA N/A
- P/E Ratio
- SWIM N/A
- IVA N/A
- Revenue Growth
- SWIM 4.12
- IVA N/A
- 52 Week Low
- SWIM $4.56
- IVA $2.11
- 52 Week High
- SWIM $8.46
- IVA $7.98
- Technical
- Relative Strength Index (RSI)
- SWIM 57.40
- IVA 51.91
- Support Level
- SWIM $6.13
- IVA $3.88
- Resistance Level
- SWIM $6.96
- IVA $4.40
- Average True Range (ATR)
- SWIM 0.32
- IVA 0.28
- MACD
- SWIM 0.09
- IVA 0.10
- Stochastic Oscillator
- SWIM 98.27
- IVA 93.06
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.